Merck
Trade Merck 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRK
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.
MRK Key Statistics
Stock Snapshot
The current Merck(MRK) stock price is $101.46, with a market capitalization of 251.82B. The stock trades at a price-to-earnings (P/E) ratio of 13.32 and offers a dividend yield of 3.2%.
During the trading session on 2025-12-19, Merck(MRK) shares reached a daily high of $102.20 and a low of $100.11. At a current price of $101.46, the stock is +1.3% higher than the low and still -0.7% under the high.
Trading volume for Merck(MRK) stock has reached 9.2M, versus its average volume of 14.82M.
Over the past 52 weeks, Merck(MRK) stock has traded between a high of $105.84 and a low of $73.31.
Over the past 52 weeks, Merck(MRK) stock has traded between a high of $105.84 and a low of $73.31.
MRK News
Merck & Co. Inc. (NYSE:MRK) will not exercise its option for Evaxion A/S (NASDAQ:EVAX) Gonorrhea vaccine candidate EVX-B2. Gonorrhoea is a common, sexually tra...
The U.S. Food and Drug Administration (FDA) is preparing to fast-track reviews of two experimental Merck & Co. Inc. (NYSE:MRK) drugs with potential blockbuster...
Here Are Thursday’s Top Wall Street Analyst Research Calls: Digital Realty, GE Vernova, Micron Technology, Merck & Co., Rivian, United Airlines, and More Quick...
Analyst ratings
57%
of 28 ratingsMore MRK News
BMO Capital upgraded Merck (MRK) to Outperform from Market Perform with a price target of $130, up from $82. The firm says the company is assembling a portfolio...
The FDA is preparing to accelerate reviews of two experimental Merck (MRK) drugs with multibillion-dollar sales potential, Patrick Wingrove and Dan Levine of Re...
Merck & Co. Inc. (NYSE:MRK) on Wednesday shared topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladd...
...
Pfizer Inc (NYSE:PFE) and Merck & Co Inc (NYSE:MRK) aren't exciting stocks anymore — and after a bruising reset, that's starting to look intentional. Pfizer's s...
Key Points Pfizer has a substantial 6.6% dividend yield but a payout ratio exceeding 100%. Eli Lilly has a payout ratio of roughly 30%, but its dividend yield...
Merck (MRK) announced positive topline results from the Phase 3 KEYNOTE-B15 trial in patients with muscle-invasive bladder cancer who are eligible for cisplatin...